# US 2001/0056185 A1 · C3A receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0056185 A1
- Document ID: US20010056185A1
- Status: Published application
- Kind: A1
- Application number: 09/803,311
- Filed: 2001-03-12
- Published: 2001-12-27
- Earliest claimed: 1997-09-23
- Inventors: Dennis Lee
- Web page: https://patentgrep.com/patent/US20010056185A1

## CPC

- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 279/14: being further substituted by carboxyl groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Novel C3A ligands are provided. Methods of using the present compounds to treat immune and inflammation disease are also provided.

## Claims

### Claim 1

A compound according to Formula (I):
3
wherein:
A represents C1-4 alkylene, optionally substituted by C1-4 alkyl or aryl; or A forms a 5-8 membered fused aliphatic ring with the adjacent phenyl ring;
m is an integer from 1 to 3;
each R1 is independently selected form the group consisting of halo, C1-4 alkyl, methanesulfonyl, alkoxy, nitrile, dimethylamine, methylenedioxy and CF3;
R2 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted phenyl, optionally substituted alkylsulfonyl, heteroarylsufonyl, optionally substituted phenylalkylaminocarbonyl, phenylaminocarbonyl, optionally substituted phenylalkyl, optionally substituted phenylsulfonyl, optionally substituted phenylalkylsulfonyl, optionally substituted naphthylalkylsulfonyl, heteroaryl carbonyl, heteroarylalkanoyl, optionally substituted alkylcarbonyl, optionally substituted phenylcarbonyl, and optionally substituted phenylalkylcarbonyl; wherein any substituents are selected from the group consisting of acyl, amide, C1-4 alkyl, halo, methylenedioxy, phenoxy and alkoxy;
or R2 forms a 5-8 membered ring with A;
or R2 forms a 4 to 7 membered ring with the carbon atom having the R4 substituent;
R3 represents hydrogen or methyl; and
R4 represents hydrogen or methyl.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein the asterisk * represents an S configuration.

### Claim 3 (depends on 2)

A compound according to claim 2 wherein R3 is hydrogen.

### Claim 4 (depends on 3)

A compound according to claim 3 wherein A is methylene.

### Claim 5 (depends on 4)

A compound according to claim 4 wherein R1 is chloro.

### Claim 6 (depends on 5)

A compound according to claim 5 wherein m is 2.

### Claim 7 (depends on 6)

A compound according to claim 6 wherein the R1 substituents are at the 3 and 5 positions on the aryl ring.

### Claim 8 (depends on 7)

A compound according to claim 7 wherein R4 is methyl.

### Claim 9 (depends on 1)

A compound according to claim 1 selected from the group consisting of:
(3,5-Dichlorobenzylamino)acetylarginine,
(1,2-Diphenylethylamino)acetylarginine,
[1-(2,2-Diphenylethylamino)]acetylarginine,
[1-(1,2,3,4-Tetrahydroisoquinolyl)]acetylarginine,
[1-Decahydroquinolinyl]acetylarginine,
[1-(1,2,3,4-Tetrahydronaphthylamino)]acetylarginine,
3,4-Dimethylbenzylaminoacetylarginine,
3,4-Dichloroenzylaminoacetylarginine,
3-Chlorobenzylaminoacetylarginine,
2,3-Dimethoxybenzylam inoacetylarginine,
[1(3,3-Diphenylpropylamino)]aminoacetylarginine,
[1-(2-(3,4-Dimethoxyphenyl))ethylamino]aminoacetylarginine,
[1-(3-Phenylpropylamino)]aminoacetylarginine,
Dibenzylaminoaminoacetylarginine,
[(3,4-Dichlorobenzylamino-N-(3-pyridinecarbonyl)]acetylarginine,
[3,5-Dichlorobenzylamino-N-(2-phenoxypropionyl)]acetylarginine,
[3,5-Dichlorobenzylamino-N-(3-pyridinecarbonyl)]acetylarginine,
3,5-Dichlorobenzylaminoacetylarginine,
[3,5-Dichlorobenzylamino-N-(2-phenoxypropionyl)]acetylarginine,
[3,4-Dichlorobenzylamino-N-(3-pyridinecarbonyl)]acetylarginine,
[3,4-Dichlorobenzylamino-N-(2-phenoxypropionyl)]acetylarginine,
[3,4-Dichlorobenzylamino-N-(2-(4chlorophenoxy)acetyl)]acetylarginine, and
[3,5-Dichlorobenzylamino-N-(3-phenylpropionyl)]acetylarginine.

### Claim 10 (depends on 9)

A compound according to claim 9 selected from the group consisting of:
[3,5-Dichlorobenzylamino-N-(3-pyridinecarbonyl)]acetylarginine,
[3,5-Dichlorobenzylamino-N-(2-phenoxyproplonyl)]acetylarginine,
(3,5-Dichlorobenzylamino)acetylarginine, and
[3,5-Dichlorobenzylamino-N-(3-phenyipropionyl)]acetylarginine.

### Claim 11

[3,5-Dichlorobenzylamino-N-(3-phenylpropionyl)]acetylarginine.

### Claim 12 (depends on 1)

A phanmnaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A method of antagonizing a C3A receptor which compnses administering to a subject in need thereof, an effective amount of a compound of claim 1.

### Claim 14 (depends on 1)

A method of treating an immune or inflammatory disease or disorder characterized by abnormal levels of anaphylatoxins which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

### Claim 15 (depends on 14)

A method according to claim 14 wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, Alzheimer's disease, psoriasis, gout, multiple sclerosis. systemic lupus erythematosus, glomerulonephritis and adult respiratory distress syndrome.
